Search

Supplemental material, sj-docx-1-tab-10.1177_1759720X221149965 for Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib by Lars E. Kristensen, Bruce Strober, Denis Poddubnyy, Ying-Ying Leung, Hyejin Jo, Kenneth Kwok, Ivana Vranic, Dona L. Fleishaker, Lara Fallon, Arne Yndestad and Dafna D. Gladman in Therapeutic Advances in Musculoskeletal Disease

Additional file 1 : Table S1. PROs included in the analysis. Table listing PROs and their descriptions included in the analysis of ScoreMDA and PASDAS.

Daniel Aletaha,1 M Elaine Husni,2 Joseph F Merola,3 Roberto Ranza,4 Heidi Bertheussen,5 Ralph Lippe,6 Pamela M Young,7 Joseph C Cappelleri,8 T Michelle Brown,9 Claire Ervin,9 Ming-Ann Hsu,10 Lara Fallon11 1Division of Rheumatology, Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria; 2Cleveland Clinic, Department of Rheumatic and Immunologic Diseases, Cleveland, OH, USA; 3Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 4Serviço de Reumatología, Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil; 5Patient Representative, Oslo, Norway; 6Inflammation & Immunology, Pfizer Pharma GmbH, Berlin, Germany; 7Inflammation & Immunology, Pfizer Inc, Collegeville, PA, USA; 8Statistics, Pfizer Inc, Groton, CT, USA; 9RTI Health Solutions, Research Triangle Park, NC, USA; 10Health Economics & Outcomes Research, Pfizer Inc, Groton, CT, USA; 11Medical Affairs, Pfizer Inc, Montreal, QC, CanadaCorrespondence: Daniel AletahaDivision of Rheumatology, Department of Internal Medicine 3, Medical University of Vienna, Währinger Gürtel 18– 20, Vienna 1090, AustriaEmail daniel.aletaha@meduniwien.ac.atObjective: Qualitative research exploring patient preferences regarding the mode of treatment administration for psoriatic arthritis (PsA) is limited. We report patient preferences and their reasons across PsA treatment modes.Methods: In this global, cross-sectional, qualitative study, interviews were conducted with adult patients with PsA in Brazil, France, Germany, Italy, Spain, the UK, and the US. Patients were currently taking a disease-modifying antirheumatic drug (DMARD). Patients indicated the order and strength of preference (0– 100; 100 = strongest) across four modes of treatment administration: oral (once daily), self-injection (weekly), clinic injection (weekly), and infusion (monthly); reasons for preferences were qualitatively assessed. Descriptive statistics were reported. Fisher’s exact tests and t-tests were conducted for treatment mode outcomes.Results: Overall, 85 patients were interviewed (female, 60.0%; mean age, 49.8 years). First-choice ranking (%) and mean [standard deviation] preference points were: oral (49.4%; 43.9 [31.9]); self-injection (34.1%; 32.4 [24.8]); infusion (15.3%; 14.5 [20.0]); clinic injection (1.2%; 9.2 [10.0]). Of 48 (56.5%) patients with a strong first-choice preference (ie point allocation ≥ 60), 66.7% chose oral administration. Self-injection was most often selected as second choice (51.8%), clinic injection as third (49.4%), and infusion as fourth (47.1%). Oral administration was the first-choice preference in the US (88.0% vs 38.0% in Europe). The most commonly reported reason for oral administration as the first choice was speed and ease of administration (76.2%); for self-injection, this was convenience (75.9%). The most commonly reported reason for avoiding oral administration was concern about possible drug interactions (63.6%); for self-injection, this was a dislike of needles or the injection process (66.7%).Conclusion: Patients with PsA preferred oral treatment administration, followed by self-injection; convenience factors were common reasons for these preferences. Overall, 43.5% of patients did not feel strongly about their first-choice preference and may benefit from discussions with healthcare professionals about PsA treatment administration options.Keywords: psoriatic arthritis, patient preference, qualitative research, treatment administration

The assumption that each enzyme expresses a single enzymatic activity in vivo is challenged by the linkage of the neuronal enzyme ubiquitin C-terminal hydrolase-L1 (UCH-L1) to Parkinson's disease (PD). UCH-L1, especially those variants linked to higher susceptibility to PD, causes the accumulation of alpha-synuclein in cultured cells, an effect that cannot be explained by its recognized hydrolase activity. UCH-L1 is shown here to exhibit a second, dimerization-dependent, ubiquityl ligase activity. A polymorphic variant of UCH-L1 that is associated with decreased PD risk (S18Y) has reduced ligase activity but comparable hydrolase activity as the wild-type enzyme. Thus, the ligase activity as well as the hydrolase activity of UCH-L1 may play a role in proteasomal protein degradation, a critical process for neuronal health.